Dr. Arvin Gouw, CEO & Founder, previously Instructor at Stanford University, has over 15 years of experience as a translational research scientist working in the field of cancer metabolism. Dr. Gouw identified a first-in-class target that causes regression of MYC-driven cancers and has filed 6 patents ranging from cancer nanotechnology detection to inhibitors of MYC and KRAS cancers. His work has been supported by the entrepreneurship programs of NSF I-Corps, SPARK at Stanford, MBC BioLabs, AbbVie, RAMP, and Johnson & Johnson. His research has been published in academic journals including Cell Metabolism, Nature Biotechnology, Nature Reviews Clinical Oncology, Science, and PNAS. Prior to Stanford, he was a visiting scholar at Harvard University. He earned his PhD from Johns Hopkins University School of Medicine, his MPhil from the University of Pennsylvania, MA, and BA from UC Berkeley.